skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: Analysis of 74 cases. A Rare Cancer Network study

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [1];  [2];  [3];  [4];  [5];  [6];  [7];  [8];  [9];  [5]
  1. Department of Radiation Oncology, University of Piemonte Orientale, Novara (Italy)
  2. Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen (Netherlands)
  3. Department of Radiation Oncology, Centre G. F. Leclerc, Dijon (France)
  4. Department of Radiation Oncology, Dr. Bernard Verbeeten Instituut, Tilburg (Netherlands)
  5. Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne (Switzerland)
  6. Department of Radiation Oncology, Hacettepe University Medical School, Ankara (Turkey)
  7. Department of Radiation Oncology, Institut Jules Bordet, Bruxelles (Belgium)
  8. Department of Radiation Oncology, Ospedale Oncologico A. Businco, Cagliari (Italy)
  9. Department of Radiation Oncology, Centre Hospitalier Universitaire de Besancon, Besancon (France)

Purpose: To retrospectively analyze a series of mucosal melanoma of the upper aerodigestive tract to determine the prognostic factors and contribute to understanding the role of radiotherapy in the therapeutic strategy. Methods and Materials: Seventy-four patients were analyzed. The most frequent locations were nasal and oral, in 31 patients (41.9%) and 12 patients (16.2%), respectively. Sixty-three patients (85.1%) were in Stage I, 5 (6.8%) in Stage II, and 6 (8.1%) in Stage III. Treatment consisted of surgery in 17 patients (23.0%), surgery and radiotherapy in 42 (56.8%), radiotherapy in 11 (14.9%), and chemo-immunotherapy in 4 (5.4%). Median follow-up was 20 months. Results: Local control at 3 years was 57% after surgery alone and 71% after surgery and radiotherapy. Overall and disease-free survival rates, respectively, were 41% and 31% at 3 years and 14% and 22% at 10 years. After univariate analysis, female gender, melanosis, tumor size {<=}3 cm, Stage I, postoperative radiotherapy, and complete remission were favorable prognostic factors. Stage I and melanosis were confirmed by multivariate analysis. Conclusions: Local control was improved by postoperative radiotherapy, despite survival being as poor as in other published series. Stage I and melanosis at diagnosis were the most favorable prognostic factors.

OSTI ID:
20842906
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 65, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2006.01.016; PII: S0360-3016(06)00123-4; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Early or Up-Front Radiotherapy Improved Survival of Localized Extranodal NK/T-Cell Lymphoma, Nasal-Type in the Upper Aerodigestive Tract
Journal Article · Tue Jan 01 00:00:00 EST 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20842906

Extrahepatic Bile Duct Cancers: Surgery Alone Versus Surgery Plus Postoperative Radiation Therapy
Journal Article · Wed Sep 01 00:00:00 EDT 2010 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20842906

Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy
Journal Article · Tue Mar 01 00:00:00 EST 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20842906